Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Q1 2026 Earnings Presentation
25 slides from Innate Pharma Sa Class A's earnings presentation, May 13, 2026
Slide 1: Q1 2026 Business Update and Financial Results
Q1 2026 Business Update and Financial Results May 13, 2026
Slide 2: Disclaimer on forward-looking information and risk factors
Disclaimer on forward-looking information and risk factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains certai
Slide 3: Conference call agenda
Q1 2026 Business Update and Financial Results Conference call agenda ► Strategic Overview and Outlook ► Lacutamab ► IPH4502 ► Next-generation ADCs ► AstraZeneca partnered assets: Monalizumab & IPH5201 ► Upcoming Catalysts & Closing Remarks ► Q&A Speakers: Jonathan Dickinson (Chief Executive Officer)
Slide 4: Strategic Overview and Outlook
Strategic Overview and Outlook Jonathan Dickinson, CEO 4
Slide 5: Focused on high-value assets
Focused on 3 high-value assets Phase 3 initiation* in H2 2026 Phase 1 ongoing Phase 3 readout in H2 2026 TELLOMAK-3 Cohort enrichment nearing completion PACIFIC-9 LACUTAMAB IPH4502 MONALIZUMAB LACUTAMAB IPH4502 MONALIZUMAB Anti-KIR3DL2 mAb in CTCL Nectin-4 ADC in solid tumors Anti-NKG2A mAb in NSCLC
Slide 6: Lacutamab, anti-KIR3DL2 Ab
Lacutamab, anti-KIR3DL2 Ab Lead proprietary antibody progressing towards potential accelerated approval and Phase 3 initiation Lacutamab is an investigational antibody under clinical evaluation. It is not approved for any indication, and its safety and efficacy have not been established. 6
Slide 7: Lacutamab is progressing toward Phase 3 initiation and a potential Accelerated Approval in Sézary syndrome
lacutamab Lacutamab is progressing toward Phase 3 initiation and a potential Accelerated Approval in Sézary syndrome Breakthrough Path to FDA clearance to Therapy Accelerated proceed with Designation for R/R SS Approval in SS Phase 3 Feb 2025 Nov 2025 Fast Track designation (FDA) Phase 2 TELLOMAK da
Slide 8: TELLOMAK-3, a confirmatory Phase 3 trial in CTCL
lacutamab TELLOMAK-3, a confirmatory Phase 3 trial in CTCL Open-label, multi-center, randomized comparative Phase 3 study of lacutamab in R/R patients with MF or SS Primary Key secondary endpoint endpoints Lacutamab KEY ELIGIBILITY SS cohort Randomization PFS CRITERIA Post moga OS 1:1 (BICR) n=108 R
Slide 9: CTCL opportunity is accessible with a focused commercial footprint in the US
lacutamab CTCL opportunity is accessible with a focused commercial footprint in the US CTCL patients in the US (Real world claims data analyses using Komodo Health data) • >85% patients treated in academic centers SS US incidence ~300 patients • Shared MF/SS prescriber base US prevalence ~1 000 pati
Slide 10: IPH4502
IPH4502 Novel and differentiated DAR8 Nectin-4 exatecan ADC IPH4502 is an investigational antibody under clinical evaluation. It is not approved for any indication, and its safety and efficacy have not been established. 10
Slide 11: IPH4502: novel and differentiated DAR8 Nectin-4 exatecan ADC
IPH4502 IPH4502: novel and differentiated DAR8 Nectin-4 exatecan ADC Target profile Binder Linker Payload Proprietary humanized anti-Nectin-4 antibody Cleavable Exatecan, a topoisomerase I inhibitor • High affinity • Hydrophilic → improved half-life, low clearance • Active in EV/MMAE-resistant model
Slide 12: IPH4502: overcoming MMAE limitations with Best-in-Class Topo I potential
IPH4502 IPH4502 : overcoming MMAE limitations with Best-in-Class Topo I potential Drug Status Payload DAR Linker IPH4502 Enfortumab vedotin Approved MMAE 4 MC-Val-Cit-PABC Pfizer/Astellas Ph3 Designed to address Sutantatug envedotin MMAE 2 PEG3-Val-Cit-PABC Tubulin Corbus Pharmaceuticals/CSPC China
Slide 13: New preclinical data reinforces best-in-class Topo I Nectin-4 ADC Potential
IPH4502 New preclinical data reinforces best-in-class Topo I Nectin-4 ADC Potential IPH4502 vs HENGRUI* IPH4502 vs LY** High Nectin-4 expression 1200 1200 Tumor volume (mm3) Tumor volume (mm3) 900 900 600 6 mg/kg 600 300 300 3 mg/kg 0 3 mg/kg 0 3 mg/kg Breast cancer 0 10 20 30 40 50 60 0 10 20 30 40
Slide 14: A First-in-Human Phase 1 clinical trial evaluating IPH4502 in solid tumors
IPH4502 A First-in-Human Phase 1 clinical trial evaluating IPH4502 in solid tumors A Phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors (NCT06781983) STUDY Dose escalation Dose optimization OBJECTIVES POPULATION n=
Slide 15: Progression After EV+P in Bladder Creates a Therapeutic gap
IPH4502 Progression After EV+P in Bladder Creates a Therapeutic gap ~2/3 of patients progress within 2 years after EV+P No established standard post EV+P Progression-Free Survival from EV-302 (n=886) Fragmented treatment patterns1 and limited outcomes2 Platinum-based chemotherapy (carbo/cis) rwOS 7.
Slide 16: IPH4502 in solid tumors: bladder cancer and beyond
IPH4502 IPH4502 in solid tumors: bladder cancer and beyond IPH4502 potential best-in-class Topo I Nectin-4 ADC Bladder cancer Multiple solid tumors Post-PADCEV setting Low-to-medium Nectin-4 expression Address growing unmet need of post-EV mUC patients* High potential in several tumor types Move up
Slide 17: Preclinical ADCs
Preclinical ADCs Next-generation ADCs to overcome current ADC limitations 17
Slide 18: A preclinical portfolio of differentiated ADC drug candidates
A preclinical portfolio of differentiated ADC drug candidates Built on IPH proprietary linker, at clinical stage via IPH4502 IPH ADC platform designed to overcome current ADC limitations Objective Expand indications by overcoming Unlock activity in Overcome TAg heterogeneity low-expressing tumors pa
Slide 19: Monalizumab and IPH5201
Monalizumab Co-developed with AstraZeneca, PACIFIC-9 Phase 3 trial ongoing in NSCLC IPH5201 Co-developed with AstraZeneca, MATISSE Phase 2 trial ongoing in NSCLC Monalizumab and IPH5201 are investigational antibodies under clinical evaluation. They are not approved for any indication, and their safe
Slide 20: PACIFIC-9: Phase 3 trial of durvalumab + oleclumab or monalizumab in unresectable stage III NSCLC
monalizumab PACIFIC-9: Phase 3 trial of durvalumab + oleclumab or monalizumab in unresectable stage III NSCLC ✓ Three Phase 2 trials supporting rationale of combination in early NSCLC (COAST, NeoCOAST, NeoCOAST-2) Phase 3 PACIFIC-9 data expected in H2 2026 Monalizumab is an investigational antibody
Slide 21: MATISSE: Phase 2 trial evaluating perioperative IPH5201 + durvalumab in resectable NSCLC
IPH5201 MATISSE: Phase 2 trial evaluating perioperative IPH5201 + durvalumab in addition to neoadjuvant platinum-based chemotherapy in resectable NSCLC Encouraging early results presented at AACR 2026 catalyze continued investigation in the MATISSE Phase 2 IPH5201 is an investigational antibody unde
Slide 22: Financial highlights of the partnership with AstraZeneca
Monalizumab IPH5201 Financial highlights of the partnership with AstraZeneca MONALIZUMAB IPH5201 Potential total amount of the agreement Potential total amount of the agreement $1.275 billion $885 million $825m Potential future milestones $825m Potential future milestones Royalties on sales Outside
Slide 23: Closing Remarks
Closing Remarks Jonathan Dickinson, CEO 23
Slide 24: A focused portfolio of 3 high-value assets driving Innate's value creation
A focused portfolio of 3 high-value assets driving Innate’s value creation LACUTAMAB IPH4502 MONALIZUMAB Anti-KIR3DL2 mAb in CTCL Nectin-4 ADC in solid tumors Anti-NKG2A mAb in NSCLC • FDA clearance to proceed with • Preliminary anti-tumor activity in • PACIFIC-9 Phase 3 in unresectable TELLOMAK-3,
Slide 25: Thank you
EURONEXT : IPH.PA NASDAQ : IPHA Thank you www.innate-pharma.com investors@innate-pharma.fr 25